This medication (semaglutide) works by activating GLP-1 receptors to regulate appetite and promote weight loss
(Post updated on June 17, 2026, with new guidance from CMS.) There have been many headlines in the last week about $50 weight-loss drugs for Medicare beneficiaries and the Medicare GLP-1 Bridge
Clinical verdict: Conditional lab approach means some patients are appropriately screened while others are not
(b) the process by which the compounded drugs are manufactured have not been reviewed by the FDA
199 In a randomized placebo-controlled trial in 20 adults with obstructive sleep apnea, 600 mg NAC given three times daily for 30 days resulted in significant reductions in AHI, apnea-related arousals, oxygen desaturation, daytime sleepiness, and snoring
For those seeking more aggressive results or who have plateaued on semaglutide, tirzepatide often becomes the preferred option because of its dual GIP/GLP-1 mechanism